Posted on 21/04/2009 in Pharmaceutical Company Financials Actelion expects 2009 to be another year of growth, it has asserted.
The company's chief financial officer Andrew J Oakley made this comment after the biopharmaceutical business reported an operating profit of CHF 121.6 million (71.5 million pounds) for the first quarter of 2009.
For the same period last year, the firm achieved operating profits of CHF 67.8 million.
The company's fiscal results for the first three months of 2009 also showed net revenues were CHF 405.6 million and operating expenses were CHF 284 million.
While investing in potential revenue drivers from its portfolio, the company also tried to expand and grow through in-licensing and acquisitions, Mr Oakley noted.
The positive start to the year means the firm is in a good position to meet its guidance, he added.
"Unforeseen events excluded, Actelion expects 2009 to be another year of growth, with total net revenues - in local currencies - to increase between 12 and 15 per cent," My Oakley concluded.
Managing director and chief executive officer Jean-Paul Clozel commented he is pleased with the "strong performance".
Last month, Andre J Mueller, head of the finance and audit committee, announced he would be retiring. Other news stories from 21/04/2009
Read more in the Zenopa News Archive
How this news is generated
|
